[
  {
    "ts": null,
    "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
    "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
    "url": "https://finnhub.io/api/news?id=99a41ad6d5957640fad350a769e0fb968bc194a5106242f6b7878d63c84d7775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767191682,
      "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
      "id": 137950161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
      "url": "https://finnhub.io/api/news?id=99a41ad6d5957640fad350a769e0fb968bc194a5106242f6b7878d63c84d7775"
    }
  },
  {
    "ts": null,
    "headline": "Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?",
    "summary": "Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.",
    "url": "https://finnhub.io/api/news?id=0bd183f235384e6c5b602f2dacfc5949b611e71b90d6fe8f17cb4207773a9435",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767184320,
      "headline": "Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?",
      "id": 137950299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.",
      "url": "https://finnhub.io/api/news?id=0bd183f235384e6c5b602f2dacfc5949b611e71b90d6fe8f17cb4207773a9435"
    }
  }
]